|
JEFF KARP, PHDDr. Jeff Karp is a Professor of Medicine at Brigham and Women’s Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology (where he teaches to HST and MIT-Sloan business school students). His work spans the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. He He has published >100 peer-reviewed papers (with >16,500 citations), has given >275 national and international invited lectures, and has >100 issued or pending national/international patents. Several technologies developed in his lab have formed the foundation for multiple products on the market and currently under development and for the launch of six companies that have raised over $180 Million in funding including Skintifique (a skincare company), Gecko Biomedical (a tissue adhesive company), Alivio Therapeutics (an inflammation targeting company), Frequency Therapeutics (a regenerative medicine company), Molecular Infusions (a cannabinoid company), and Landsdowne Labs (a child safety company). In addition to his research goals, Karp is dedicated to the career development of next generation bioengineers to work at the forefront of regenerative medicine.
|
|
Nazila Kamaly, PHDDr. Nazila Kamaly is a group leader and lecturer in chemistry at Imperial College London (consistently ranked in the top 10 universities in the world), and an Associate Professor at The Technical University of Denmark, Department of Health Technology. Her research is highly multidisciplinary and uses bioinspired approaches to synthesize targeted multi-functional polymeric nanomedicines capable of changing their surface or core properties in response to local or up-regulated disease markers for stimuli-responsive and spatiotemporally controlled biological drug delivery. She has published over 40 peer-reviewed scientific articles in high impact Journals such as Science Translational Medicine, PNAS and ACS Nano. Her work has received over 5500 citations. Prior to her current position, she was an Instructor in the Laboratory of Nanomedicine and Biomaterials at Harvard Medical School (2013-2015) where she pioneered targeted polymeric anti-inflammatory nanomedicines for heart disease. She also carried out a number of postdoctoral research positions within the same laboratory (2011-2013), and MIT (2011-2015), and also previously at Imperial College London Chemistry Department (2007-2010), where she designed, synthesised and tested nanomedicines, nanodiagnostics and nanotheranostics for inflammation, heart disease and dual cancer imaging and therapy. She obtained an MSci degree in Medicinal Chemistry from University College London (2002), and a PhD in Bioorganic Chemistry from Imperial College London, Department of Chemistry (2008). In 2016 she was the recipient of a Lundbeck Fellowship to develop novel translational nanomedicines for heart disease. Her research efforts have secured over $7.3 million in academic grants. Her goal is to bring novel targeted nano medicines to the market and to train and educate the next generation of nanotech scientists.
|
|
WARRIS BOKHARI, MDDr. Warris Bokhari most recently served as Chief of Staff of Apple's Healthcare, and previously was the Director of New Business Models at GE Healthcare, where he built strategic partnerships around data analytics/deep learning (as applied to biopharmaceutical process), digital health, population health outcomes, and next generation sequencing. Warris is a medical doctor trained in London (UCL) and practiced as an anesthetist at Imperial College. He left full-time practice to help incubate medical device, genomics, and therapeutics companies at Loxbridge Research in London where, among others, he incubated the company Freenome. Warris co-founded Omnity.io, using computational linguistics and network mathematics to accelerate knowledge discovery and Rareshare.io, a platform for elastic on-demand science that reduces the capital costs involved in developing new technologies.
|
|
AGNIESZKA CZECHOWICZ, MD, PHDDr. Agnieszka Czechowicz is an Assistant Professor at Stanford University. She is a pediatric hematologist/oncologist, and sub-focuses on pediatric stem cell transplantation. She also runs a translational research group focusing on understanding hematopoeitic stem cells and how they interact with their microenvironments. Agnieszka completed her residency in Pediatrics at Boston Children's Hospital, and pursued fellowship training at the Dana Farber Cancer Institute and Lucile Packard Children's Hospital. She consulted for Third Rock ventures and incubated numerous companies including Editas, Magenta Therapeutics, and Global Blood Therapeutics, and currently advises GV. She graduated from Stanford University School of Medicine with a MD/PhD in developmental biology in the Medical Scientist Training Program, in record breaking time. She also earned an undergraduate degree with honors from Stanford University, in biological sciences and received the Firestone medal for her outstanding senior thesis. Agnieszka is an author on numerous publications, including a first author on a paper published in the November 2007 issue of Science which shows a possible way to eliminate the toxicity of bone marrow transplantation (BMT), a discovery that could expand the applications of BMT to include cures for most blood diseases, as well as autoimmune diseases like diabetes. She is in the process of translating these discoveries and developing them into new therapies for patients.
|